Related references
Note: Only part of the references are listed.Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer
Jyoti S. Mayadev et al.
JAMA ONCOLOGY (2020)
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
Jyoti Mayadev et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
Sangwoo S. Kim et al.
CLINICAL CANCER RESEARCH (2020)
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
Linda R. Duska et al.
CANCER (2020)
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Diane M. Da Silva et al.
CLINICAL CANCER RESEARCH (2020)
Strength of immune selection in tumors varies with sex and age
Andrea Castro et al.
NATURE COMMUNICATIONS (2020)
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
Willemijn S M E Theelen et al.
Lancet Respiratory Medicine (2020)
Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy
Zachary S. Buchwald et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: A phase Ill, randomized, double-blind, multicenter study.
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S. Peters et al.
LUNG CANCER (2019)
Radiotherapy with Concurrent and Adjuvant Pembrolizumab in Patients with P16-Positive Locoregionally Advanced Head and Neck Cancer: KEYCHAIN Trial Lead-In Results
A. G. Sacco et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
PACIFIC-4/RTOG 3515: Phase III Study of Durvalumab Following SBRT for Unresected Stage I/II, Lymph-Node Negative NSCLC
C. Robinson et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Respons
James W. Welsh et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Ariel E. Marciscano et al.
CLINICAL CANCER RESEARCH (2018)
Combining Immunotherapy and Radiotherapy for Cancer Treatment Current Challenges and Future Directions
Yifan Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22)
Jose A. Lopez-Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 PembroRad trial.
Xu Shan Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Mouse Models for Cancer Immunotherapy Research
Brian Olson et al.
CANCER DISCOVERY (2018)
Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition
Donata von Reibnitz et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Abul Azad et al.
EMBO MOLECULAR MEDICINE (2017)
Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma
David Friedman et al.
HEPATOLOGY RESEARCH (2017)
Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases
Benjamin Frey et al.
IMMUNOLOGICAL REVIEWS (2017)
Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
Noelle L. Williams et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Combined Immune Checkpoint Blockade and Radiation Therapy: Timing and Dose Fractionation Associated with Greatest Survival Duration Among Over 750 Treated Patients
R. Samstein et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
Andrew Bang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases
Kamran A. Ahmed et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma
Penny Fang et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells
Giuliana P. Mognol et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y. Xu-Monette et al.
FRONTIERS IN IMMUNOLOGY (2017)
Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers
Christina H. Son et al.
CANCER MANAGEMENT AND RESEARCH (2017)
A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929.
Jyoti Mayadev et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.
Austin G. Duffy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy
Sarita M. Fernandez-Poma et al.
CANCER RESEARCH (2017)
Nivolumab induced radiation recall pneumonitis after two years of radiotherapy
R. Shibaki et al.
ANNALS OF ONCOLOGY (2017)
Timing and Type of Immune Checkpoint Therapy Affect the Early Radiographic Response of Melanoma Brain Metastases to Stereotactic Radiosurgery
Jack M. Qian et al.
CANCER (2016)
Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial
Antonin Levy et al.
EUROPEAN JOURNAL OF CANCER (2016)
Radionecrosis after stereotactic radiotherapy for brain metastases
E. Le Rhun et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Radionecrosis after stereotactic radiotherapy for brain metastases
E. Le Rhun et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
Kristina H. Young et al.
PLOS ONE (2016)
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
Chun-Te Wu et al.
SCIENTIFIC REPORTS (2016)
Immune Priming of the Tumor Microenvironment by Radiation
Wen Jiang et al.
TRENDS IN CANCER (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Temporally-Dependent Intracranial Control of Melanoma Brain Metastasis by Stereotactic Radiation Therapy in Patients Treated With Immune Checkpoint Blockade
W. Jiang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment
Ana P. Kiess et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases
Zachary A. Kohutek et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors
Penny K. Sneed et al.
JOURNAL OF NEUROSURGERY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review
Jonathan D. Schoenfeld et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Andrew B. Sharabi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
Yansheng Hao et al.
CLINICAL CANCER RESEARCH (2014)
Radiotherapy-Induced Anti-Tumor Immunity Contributes to the Therapeutic Efficacy of Irradiation and Can Be Augmented by CTLA-4 Blockade in a Mouse Model
Yuya Yoshimoto et al.
PLOS ONE (2014)
Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
Inge Verbrugge et al.
CANCER RESEARCH (2012)
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival Clinical article
Jonathan P. S. Knisely et al.
JOURNAL OF NEUROSURGERY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
David J. Andorsky et al.
CLINICAL CANCER RESEARCH (2011)
Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization
Qifeng Zhou et al.
JOURNAL OF IMMUNOLOGY (2010)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
Youjin Lee et al.
BLOOD (2009)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
Ryo Yamamoto et al.
CANCER SCIENCE (2009)
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
Randall H. Friedline et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Blockade of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo
Simon Read et al.
JOURNAL OF IMMUNOLOGY (2006)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Share Paper
